阿昔替尼用于一线全身治疗失败后的晚期转移性肾细胞癌（mRCC）患者的治疗。
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.
作者信息
Grünwald Viktor, Merseburger Axel S
机构信息
Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
出版信息
Onco Targets Ther. 2012;5:111-7. doi: 10.2147/OTT.S23273. Epub 2012 Jun 18.
Abstract
The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib's efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.
摘要
近年来，肾细胞癌（RCC）的治疗格局发生了巨大变化。贝伐单抗/干扰素、舒尼替尼、索拉非尼、替西罗莫司、依维莫司和帕唑帕尼已被证明对转移性肾细胞癌有效。阿昔替尼是一种新型酪氨酸激酶抑制剂，可在亚纳摩尔水平抑制血管内皮生长因子受体（VEGFR）。基于这种对VEGFR的非凡抑制作用，阿昔替尼被视为下一代药物。最近的AXIS试验报告了阿昔替尼在肾细胞癌二线治疗中的疗效，这导致其最近在美国获得批准。本综述重点关注阿昔替尼在肾细胞癌患者中的临床疗效。
相似文献
1
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.阿昔替尼用于一线全身治疗失败后的晚期转移性肾细胞癌（mRCC）患者的治疗。
Onco Targets Ther. 2012;5:111-7. doi: 10.2147/OTT.S23273. Epub 2012 Jun 18.
2
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.欧洲药品管理局批准阿昔替尼（英立达）用于治疗在先前使用舒尼替尼或细胞因子治疗失败后的晚期肾细胞癌：人用药品委员会科学评估摘要
Oncologist. 2015 Feb;20(2):196-201. doi: 10.1634/theoncologist.2014-0177. Epub 2015 Jan 23.
3
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.晚期肾细胞癌（RCC）的靶向治疗：一项对已发表随机试验的 Cochrane 系统评价。
BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27.
4
The prospects of pazopanib in advanced renal cell carcinoma.帕唑帕尼在晚期肾细胞癌中的应用前景。
Ther Adv Urol. 2013 Oct;5(5):223-32. doi: 10.1177/1756287213495099.
5
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.替沃扎尼布治疗既往接受阿昔替尼治疗的晚期肾细胞癌患者：TIVO-3 的亚组分析。
Oncologist. 2023 Mar 17;28(3):e167-e170. doi: 10.1093/oncolo/oyac255.
6
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.转移性肾细胞癌患者通过序贯靶向治疗改善生存终点。
Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10.
7
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.美国既往舒尼替尼治疗失败的晚期肾细胞癌患者中依维莫司与阿昔替尼的终身成本。
J Med Econ. 2015 Mar;18(3):200-9. doi: 10.3111/13696998.2014.985789. Epub 2014 Nov 26.
8
[Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].[晚期转移性肾细胞癌治疗的跨学科建议]
Aktuelle Urol. 2020 Dec;51(6):572-581. doi: 10.1055/a-1252-1780. Epub 2020 Oct 7.
9
A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.一项针对转移性肾细胞癌一线和二线治疗疗效和安全性的网络荟萃分析。
J Clin Pharm Ther. 2021 Feb;46(1):35-49. doi: 10.1111/jcpt.13282. Epub 2020 Oct 28.
10
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.最大限度延长转移性肾细胞癌患者的疾病控制时间：专家共识。
Med Oncol. 2012 Sep;29(3):1896-907. doi: 10.1007/s12032-011-0016-8. Epub 2011 Jul 7.
引用本文的文献
1
Role of lymphatic endothelial cells in the tumor microenvironment-a narrative review of recent advances.淋巴管内皮细胞在肿瘤微环境中的作用——近期进展的叙述性综述
Transl Lung Cancer Res. 2021 May;10(5):2252-2277. doi: 10.21037/tlcr-21-40.
2
Synthesis of 1-Indazoles via Silver(I)-Mediated Intramolecular Oxidative C-H Bond Amination.通过银（I）介导的分子内氧化C-H键胺化反应合成1-吲唑类化合物。
ACS Omega. 2021 Feb 23;6(9):6498-6508. doi: 10.1021/acsomega.1c00025. eCollection 2021 Mar 9.
3
Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer.癌症中癌细胞与淋巴管的通讯：聚焦膀胱癌
Onco Targets Ther. 2019 Oct 3;12:8161-8177. doi: 10.2147/OTT.S219111. eCollection 2019.
4
The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.美国食品和药物管理局批准的 PI3K 抑制剂 GDC-0941 增强了阿昔替尼对 c-myc 扩增高危成神经管细胞瘤的体外抗肿瘤疗效。
J Cell Mol Med. 2018 Apr;22(4):2153-2161. doi: 10.1111/jcmm.13489. Epub 2018 Jan 29.
5
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.阿昔替尼治疗肾细胞癌：设计、研发及治疗地位
Drug Des Devel Ther. 2017 Sep 21;11:2801-2811. doi: 10.2147/DDDT.S109640. eCollection 2017.
6
Axitinib in metastatic renal cell carcinoma: single center experience.阿昔替尼治疗转移性肾细胞癌：单中心经验
Contemp Oncol (Pozn). 2016;20(6):481-485. doi: 10.5114/wo.2016.65609. Epub 2017 Jan 12.
7
The lymphatic system and pancreatic cancer.淋巴系统与胰腺癌
Cancer Lett. 2016 Oct 10;381(1):217-36. doi: 10.1016/j.canlet.2015.11.048. Epub 2015 Dec 29.
8
Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.c-Met和RON激酶在肿瘤进展中的作用及其作为治疗靶点的潜力。
Oncotarget. 2015 Feb 28;6(6):3507-18. doi: 10.18632/oncotarget.3420.
9
Axitinib: newly approved for renal cell carcinoma.阿昔替尼：新获批用于治疗肾细胞癌。
J Adv Pract Oncol. 2012 Sep;3(5):333-5. doi: 10.6004/jadpro.2012.3.5.7.
10
Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report.阿昔替尼治疗具有圆细胞分化且直接侵犯十二指肠和下腔静脉的肾细胞癌的术前降期：一例报告。
Onco Targets Ther. 2014 Feb 15;7:289-95. doi: 10.2147/OTT.S58089. eCollection 2014.
本文引用的文献
1
Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.药物代谢酶或转运体遗传多态性对阿昔替尼药代动力学影响的荟萃分析。
Eur J Clin Pharmacol. 2012 May;68(5):645-55. doi: 10.1007/s00228-011-1171-8. Epub 2011 Dec 15.
2
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.阿昔替尼对比索拉非尼用于晚期肾细胞癌的疗效（AXIS）：一项随机 3 期试验。
Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4.
3
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.晚期肾细胞癌（RCC）的靶向治疗：一项对已发表随机试验的 Cochrane 系统评价。
BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27.
4
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.转移性肾细胞癌患者的序贯治疗：受体酪氨酸激酶抑制剂治疗失败后常见靶向治疗方案的比较。
Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21.
5
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.酪氨酸激酶抑制剂的内在耐药性与转移性肾细胞癌的不良临床结局相关。
BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295.
6
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.2010 年国际肾脏肿瘤研讨会（ICUD-EAU）：转移性疾病的治疗。
Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017. Epub 2011 Jun 24.
7
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.无进展生存期作为当代靶向治疗转移性肾细胞癌患者总生存期的预测指标。
Cancer. 2011 Jun 15;117(12):2637-42. doi: 10.1002/cncr.25750. Epub 2010 Nov 18.
8
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.序贯使用索拉非尼和舒尼替尼治疗晚期肾细胞癌（RCC）：意大利多中心回顾性分析 189 例患者。
BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23.
9
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.舒张期血压作为固体肿瘤阿昔替尼疗效的生物标志物。
Clin Cancer Res. 2011 Jun 1;17(11):3841-9. doi: 10.1158/1078-0432.CCR-10-2806. Epub 2011 Apr 29.
10
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.高血压作为舒尼替尼治疗转移性肾细胞癌患者疗效的生物标志物。
J Natl Cancer Inst. 2011 May 4;103(9):763-73. doi: 10.1093/jnci/djr128. Epub 2011 Apr 28.
Zotero 插件